ACCESS Newswire

Exosens

9.4.2024 09:03:39 CEST | ACCESS Newswire | Press release

Share
Exosens Adds Innovative Photon Counting System, LINCam, to Its Portfolio of Single Photon Sensitive Detectors

RODEN, NETHERLANDS / ACCESSWIRE / April 9, 2024 / Exosens is pleased to announce a partnership with Photonscore, a provider of instrumentation for time-correlated single photon imaging. Through this partnership, Exosens will distribute LINCam, an innovative camera system with picosecond time resolution through their Photonis-branded scientific imaging product portfolio.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Exosens & Photonscore Partnership

"We are delighted to partner with Photonscore and add LINCam to our scientific imaging solutions to our potential customers. LINCam is a breakthrough technology that enables fast and accurate time-resolved imaging for a variety of applications, such as biomedical research, material science, and quantum optics. LINCam complements our existing product line and combined will provide a unique value proposition." - Ulrich Laupper, President and Executive General Manager of the Exosens Ultimate Detection Business Unit.

LINCam is an easy-to-use, event-based camera that counts photons at high rate with the picosecond time resolution combined with accurate position information. Paired with a pulsed light source, LINCam can turn any conventional microscope into a powerful lifetime imager.

The partnership between Exosens and Photonscore is supported by Photonis, a brand of Exosens, which provides a crucial component of the camera: the high-time resolution position-sensitive MCP-PMT detector. Photonis has optimized the MCP-PMT which allows for the best properties for LINCam performance by providing high quantum efficiency and low dark rate photocathodes in a broad spectral range and also by implementing high linearity and high gain MCPs to increase the dynamic operational range. As a result of Exosens and Photonscore's close technical collaboration, the state-of-the-art high-time resolution single-photon camera LINCam becomes the optimal solution for widefield microscopy and other highly demanding applications.

"At Photonscore we are excited to start a productive partnership with Exosens. Their knowledge and experience in the field of photon detection gave us a big leap in the quality and capability of our system. In particular, the outstanding technology of Hi-QE photocathodes and high-performance MCPs enables us to bring LINCam to the applications where we did not dare enter into before." - Yury Prokazov, CEO, Photonscore GmbH

ABOUT PHOTONSCORE:

Photonscore GmbH specializes in simplifying single photon counting for its customers. The company's primary product, the LINCam, is a single photon counting camera with a 100% fill-factor and minimal noise. The company is serving leading universities and research institutes across the world, reflecting the broad applicability of its technologies. Photonscore's contributions to the field have been recognized with several awards. These include the 1st Prize in the Hugo-Junkers-Award 2017 for innovative applied research and nomination as a finalist in the German Innovation Award 2019. Photonscore is committed to advancing photon counting technology, striving to make it more accessible and effective for a wide range of applications.

ABOUT PHOTONIS:

Photonis is a leading brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture, and sale of high-end electro-optical technologies used in the detection of ions, electrons, and photons. The Photonis brand portfolio offers photo-detection and low-light conditions imaging solutions for extremely demanding markets such as Defense & Security, Nuclear Safety, Life Science, and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.

For more information: exosens.com

Contact: scientificdetectors@exosens.com

Contact Information

Sales Manager
scientificdetectors@exosens.com
+31 50 501 8808

SOURCE: Photonis

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Medical Component Specialists to Support Advanced Catheter Innovation at The Catheter R&D Masterclass in Ireland4.5.2026 21:30:00 CEST | Press release

BELLINGHAM, MA / ACCESS Newswire / May 4, 2026 / Medical Component Specialists (MCS), a premier manufacturer of precision medical components, today announced its participation as a supporting organization at The Catheter R&D Masterclass. Hosted by Eyedea Medtech, the highly anticipated event will take place May 28-29, 2026, at the Prototyping and Education Facility in Westport, Mayo, Ireland. The Catheter Systems Lab is an exclusive, dual-purpose educational program designed for senior engineers with over a decade of experience in catheter-based medical device development. Over the course of two days, industry leaders will engage in a deep exploration of catheter design, materials science, structural reinforcement, and end-to-end manufacturing pathways. As a supporting organization, Medical Component Specialists will play a vital role in the event's structured insight and data capture initiatives. The masterclass will facilitate meaningful technical dialogue, allowing MCS to gain direc

Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business4.5.2026 09:30:00 CEST | Press release

LOS ANGELES, CA AND PARIS, FR / ACCESS Newswire / May 4, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, announced today that an affiliate of Pacific Avenue has entered into exclusive negotiations to acquire ESE World (the "Company" or "ESE") from Amcor, one of the world's leading global packaging companies. ESE is the foremost European manufacturer of both plastic and steel waste containers and a provider of associated waste management services. The Company generates approximately €300m of revenues and serves customers across the world from its three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey). Under Pacific Avenue's stewardship, ESE will focus its efforts on meeting the needs of its customers and executing several growth initiatives tied to operational improvement, geographic expansion, and strategic add-on acquisitions. Pacifi

Securitas Acquires CamVision to Expand Packaged and Advanced Security Solutions in Denmark4.5.2026 09:00:00 CEST | Press release

STOCKHOLM, SE / ACCESS Newswire / May 4, 2026 / Securitas has acquired CamVision, a Danish technology driven security specialist with a strong position in retail loss prevention and electronic security solutions. The acquisition strengthens Securitas' ability to deliver reliable and scalable security solutions for micro and small singlesite businesses as well as larger, multisite clients across Denmark. For micro and small businesses, the acquisition enhances Securitas' offering of standardized, packaged security solutions that combine proven technology with dependable service delivery. For larger and multisite clients, it further strengthens Securitas' capability to deliver advanced, technology led security systems designed for complex operational environments. "With the acquisition of CamVision, we strengthen our offering for micro and small business clients, particularly within retail. By combining proven security technology with standardized service delivery, we can offer simpler,

Formerra Appoints Matt Borowiec as Chief Commercial Officer1.5.2026 15:00:00 CEST | Press release

CLEVELAND, OH / ACCESS Newswire / May 1, 2026 / Formerra, a leading distributor of performance materials, today announced the appointment of Matt Borowiec as Chief Commercial Officer (CCO). Borowiec will lead the company's commercial organization to support continued growth and global expansion while strengthening sales execution and customer success. Borowiec is a seasoned executive with over 25 years' experience in operations, commercial and P&L roles across resin manufacturing, specialty compounding, and distribution, including leadership roles at GE Plastics, PolyOne (now Avient), Transcendia, Celanese, and Kinsley Group. With this background, he is well positioned to lead Formerra's commercial strategy at this important time in the company's evolution. "Matt brings a unique combination of producer‑side and distribution experience that positions him well to strengthen alignment between our suppliers, customers, and commercial teams," said Tom Kelly, Chief Executive Officer at Forme

Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release

INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye